Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 8/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 2/20 | 0.50 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | F11 | P03951 | 2/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | KLK2 | P20151 | 1/20 | 0.49 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.49 |
| ▸ | KLK13 | Q9UKR3 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.49 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860724 | 0.97 | F12 (0.52) | F12CXCR4KCNMA1KCNMB4CTSG | |
| SCHEMBL29389051 | 0.96 | CTSG (0.51) | F12CXCR4KCNMA1KCNMB4CTSG | |
| Iseganan SCHEMBL29378977 | 0.93 | CTSG (0.56) | F12CXCR4KCNMA1KCNMB4CTSG | |
| Iseganan SCHEMBL29420585 | 0.93 | CTSG (0.55) | F12CXCR4KCNMA1KCNMB4CTSG | |
| SCHEMBL29388123 | 0.92 | BECN1 (0.53) | F12CXCR4CTSGKLK7F11 | |
| SCHEMBL29385556 | 0.91 | CXCR4 (0.60) | F12CXCR4KLKB1 | |
| Hydrochloric Acid SCHEMBL27846143 | 0.89 | CTSG (0.54) | CXCR4KCNMA1KCNMB4CTSGKLKB1 | |
| SCHEMBL29385468 | 0.87 | KCNMA1 (0.57) | F12KCNMA1KCNMB4KLKB1 | |
| SCHEMBL29352842 | 0.78 | BECN1 (0.63) | KCNMA1KCNMB4BECN1 | |
| Polyphemusin Ii SCHEMBL29449206 | 0.77 | F12 (0.62) | F12KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377186-B2 | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-08-05 | — | — | US | claimed |
| CN-116966267-A | Antibacterial peptide nano polymer, preparation method and application | 中国人民解放军空军军医大学 | 2023-10-31 | — | — | CN | claimed |
| US-20230270828-A1 | COMPOSITION FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | BICT S.R.L. (IT) | 2023-08-31 | — | — | US | claimed |
| US-11246819-B2 | Compositions and methods for inhibiting biofilm deposition and production | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-02-15 | — | — | US | claimed |
| EP-3317293-B1 | AN ANIMAL FEED OR ANIMAL FEED ADDITIVE COMPRISING ONE OR MORE POLYPEPTIDES HAVING LYSOZYME ACTIVITY AND USES THEREOF | NOVOZYMES AS (DK) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026099341-A1 | BIOCONTAINMENT OF UNWANTED ENGINEERED CELLS USING NON-NATURAL AMINO ACIDS | SNIPR BIOME APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| EP-3937966-B1 | COMPOSITIONS AND METHODS FOR PROTECTING TYPE 2 ALVEOLAR EPITHELIAL CELLS (AEC2) | REIN THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260110698-A1 | METHODS FOR QUANTIFYING FRATAXIN ACTIVITY | LARIMAR THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108469-A1 | COMPOSITIONS COMPRISING WATER INSOLUBLE DRUGS AND METHODS OF PRODUCING AND USING SAME | NANO GHOST LTD (IL) | 2026-04-23 | — | — | US | disclosed |
| US-12606640-B2 | Recombinant antimicrobial multidomain polypeptide, methods of producing and uses thereof | IRTA, INSTITUT DE RECERCA I TRANSFERÈNCIA AGROALIMENTÀRIES (ES) | 2026-04-21 | — | — | US | disclosed |
| EP-4719450-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Rein Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4712792-A1 | A NOVEL FEED COMPOSITION | DSM IP Assets B.V. (NL) | 2026-03-25 | — | — | EP | disclosed |
| US-20220046954-A1 | ANIMAL FEED COMPOSITION AND USE THEREOF | NOVOZYMES A/S (DK) | 2022-02-17 | — | — | US | disclosed |
| US-20220047685-A1 | ANIMAL FEED COMPOSITION AND USE THEREOF | NOVOZYMES A/S (DK) | 2022-02-17 | — | — | US | disclosed |
| US-20220049230-A1 | PHYTASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES A/S (DK) | 2022-02-17 | — | — | US | disclosed |
| US-11246819-B2 | Compositions and methods for inhibiting biofilm deposition and production | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2022029577-A1 | COMPOSITION FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | BICT S.R.L. (IT) | 2022-02-10 | — | — | WO | disclosed |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | CAMURUS AB (SE) | 2022-02-08 | — | — | US | disclosed |
| US-11230575-B2 | Insoluble fusion protein comprising antimicrobial peptide and method for producing antimicrobial peptide using same | KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) | 2022-01-25 | — | — | US | disclosed |
| US-11229223-B2 | Enzyme granules for animal feed | NOVOZYMES A/S (DK) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108469-A1 | COMPOSITIONS COMPRISING WATER INSOLUBLE DRUGS AND METHODS OF PRODUCING AND USING SAME | ABCB1, WEE1, PARP3 | F12 1341/4885CXCR4 297/4885KCNMA1 4815/4885 |
| US-11246819-B2 | Compositions and methods for inhibiting biofilm deposition and production | ADAM33, FGB, ADAM17 | F12 137/4885CXCR4 3331/4885KCNMA1 3180/4885 |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | PHOSPHO1, LIPA, ABHD16A | F12 63/4885CXCR4 3152/4885KCNMA1 478/4885 |
| US-20260110698-A1 | METHODS FOR QUANTIFYING FRATAXIN ACTIVITY | ATXN2L, XDH, CYFIP1 | F12 253/4885CXCR4 2394/4885KCNMA1 2046/4885 |
| US-12606640-B2 | Recombinant antimicrobial multidomain polypeptide, methods of producing and uses thereof | SPPL2B, SPPL2A, LCT | F12 1387/4885CXCR4 3213/4885KCNMA1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.